NCT06382155View on ClinicalTrials.gov

A Phase 2 Study of Vosoritide in Children with Idiopathic Short Stature

PHASE2RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

October 21, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2036

Conditions
Idiopathic Short Stature
Interventions
DRUG

Vosoritide Injection

Experimental Drug Lyophilized powder for reconstitution

DRUG

Human Growth Hormone

Commercial product containing somatotropin

DRUG

Placebo

Lyophilized powder for reconstitution

Trial Locations (8)

10467

RECRUITING

Children's Hospital at Montefiore, The Bronx

14203

RECRUITING

UBMD Pediatrics, Buffalo

31904

RECRUITING

Centricity Research, Columbus

32514

RECRUITING

Nemours Children's Health System - Corporate Headquarters, Pensacola

83404

RECRUITING

Rocky Mountain Clinical Research - Idaho Falls, Idaho Falls

83712

RECRUITING

St. Luke's Children's Endocrinology, Boise

90502

RECRUITING

Lundquist Institute for Biomedical Innovation (LA BioMed), Torrance

95821

RECRUITING

Center Of Excellence in Diabetes and Endocrinology, Sacramento

Sponsors
All Listed Sponsors
lead

BioMarin Pharmaceutical

INDUSTRY